A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of SLx-4090 in Combination With Metformin in Subjects With Type 2 Diabetes.
Phase of Trial: Phase II
Latest Information Update: 04 May 2015
At a glance
- Drugs KD 026 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Surface Logix
- 10 Jun 2017 Biomarkers information updated
- 04 May 2015 Primary endpoint has been met (Reduction in HbA1c) according to Kadmon Media Release.
- 04 May 2015 Results published in the Kadmon Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History